← 홈

VEGF

241개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 241개
AntibodystaleInnoventPreclinical

Sintilimab combined with Bevacizumab (Sintilimab combined with Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleInnoventPhase 2

Sintilimab combined with bevacizumab and albumin-bound paclitaxel plus gemcitabine (Sintilimab combined with bevacizumab and albumin-bound paclitaxel plus gemcitabine)

ORR,OS,PFS · ORR,OS,PFS

#ORROSPFS#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleInnoventPhase 2

Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab (Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab)

Colorectal Cancer Liver Metastasis · Colorectal Cancer Liver Metastasis

#ColorectalCancerLiverMetastasis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleInnoventPhase 2

Sintilimab, Bevacizumab , Pemetrexed , Cisplatin (Sintilimab, Bevacizumab , Pemetrexed , Cisplatin)

Malignant Peritoneal Mesothelioma, Advanced · Malignant Peritoneal Mesothelioma, Advan

#MalignantPeritonealMesotheliomaA#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 2

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Brain Cancer; Glioblastoma · Brain Cancer

#BrainCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRocheApproved

Subconjunctival Bevacizumab (Subconjunctival Bevacizumab)

Glaucoma · Glaucoma

#Glaucoma#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Altuzan (Subconjunctival bevacizumab, Subconjunctival bevacizumab (Altuzan))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleUMC UtrechtPhase 2

FTD-TPI and bevacizumab (Systemic treatment, Systemic treatment (FTD-TPI and bevacizumab))

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSun Yat-sen UniversityPhase 2

atezolizumab (Tecentriq, TACE-HACI, plus atezolizumab-bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

TAS-102+bevacizumab+local treatment (TAS-102+bevacizumab+local treatment)

Metastatic Colorectal Cancer (CRC) · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

TAS-102, oxaliplatin, irinotecan with bevacizumab (TAS-102, oxaliplatin, irinotecan with bevacizumab)

Colon Cancer; Rectal Cancer · Colon Cancer

#ColonCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleChia Tai Tianqing Pharmaceutica…Phase 2

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

RAS/BRAF Wild Type Colorectal Cancer · RAS/BRAF Wild Type Colorectal Cancer

#RASBRAFWildTypeColorectalCancer#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleGlaxoSmithKlinePreclinical

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Carcinoma, Renal Cell · Carcinoma, Renal Cell

#CarcinomaRenalCell#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Targeted therapy with bevacizumab (Targeted therapy with bevacizumab)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab plus Bevacizumab (Tislelizumab plus Bevacizumab)

Astrocytoma of Brain · Astrocytoma of Brain

#AstrocytomaofBrain#Antibody#Phase2#항체#면역항체+2
효능 ORR 37.1%임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Tislelizumab; Bevacizumab · Tislelizumab

#Tislelizumab#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRocheApproved

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab)

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Triamcinolone Acetonide and Bevacizumab (Triamcinolone Acetonide and Bevacizumab)

Diffuse Diabetic Macular Edema · Diffuse Diabetic Macular Edema

#DiffuseDiabeticMacularEdema#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED

10 / 13 페이지

← 이전다음 →